ArticleHepatology (Baltimore, Md.)2017
Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.
Article in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.Hepatology international · 2024Guideline
- Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: a systematic review.Hepatology international · 2022Pooled it
- Viral hepatitis after liver transplantation: A brief overview.World journal of virology · 2026Review
- Article
- Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value.World journal of hepatology · 2023Review
- Hepatitis C: recent advances and practical management.Frontline gastroenterology · 2023Review
- Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era.Life (Basel, Switzerland) · 2022Article
- Review article: current and emerging therapies for the management of cirrhosis and its complications.Alimentary pharmacology & therapeutics · 2022Review
- Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?Biomedicines · 2022Review
- Transplanting Organs from Donors with HIV or Hepatitis C: The Viral Frontier.World journal of surgery · 2021Review
- A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis.Gastroenterology research · 2021Review
- Pretransplant Hepatitis C Virus Treatment Decreases Access to High-quality Livers.Transplantation direct · 2021Article
- Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach.Journal of market access & health policy · 2021Article
- Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool.Journal of transplantation · 2021Article
- Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy.Clinical and molecular hepatology · 2020Review
- Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.BMC gastroenterology · 2020Article
- Eliminating viral hepatitis C in Belgium: the micro-elimination approach.BMC infectious diseases · 2020Article
- Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2019Article
- Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis.Gastroenterology · 2019Article
Corrections and comments
- Commented on by
- Commented on byReply.2017
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
The availability of oral direct-acting antivirals has altered the hepatitis C virus (HCV) treatment paradigm for both pre-liver transplant (LT) and post-LT patients. There is a perceived trade-off between pre-LT versus post-LT treatment of HCV-treatment may improve liver function but potentially decrease the likelihood of a necessary LT. Our objective was to identify LT-eligible patients with decompensated cirrhosis who would benefit (and not benefit) from pre-LT treatment based on their Model for End-Stage Liver Disease (MELD) scores. We simulated a virtual trial comparing long-term outcomes of pre-LT versus post-LT HCV treatment with oral direct-acting antivirals for patients with MELD scores between 10 and 40. We developed a Markov-based microsimulation model, which simulated the life course of patients on the transplant waiting list and after LT. Simulation of LT integrated data from recent trials of oral direct-acting antivirals (SOLAR 1 and 2), the United Network for Organ Sharing (UNOS), and other studies. The outcomes of the model included life expectancy, 1-year and 5-year patient survival, and mortality. Model-predicted patient survival was validated with UNOS data. We found that, at the national level, treating HCV before LT increased life expectancy if MELD was ≤27 but could decrease life expectancy at higher MELD scores. Depending on the UNOS region, the threshold MELD score to treat HCV pre-LT varied between 23 and 27 and was lower for UNOS regions 3, 10, and 11 and higher for regions 1, 2, 4, 5, 8, and 9. Sensitivity analysis showed that the thresholds were stable.
conclusionOur findings suggest that the optimal MELD threshold below which decompensated cirrhosis patients should receive HCV treatment while awaiting LT is between 23 and 27, depending on the UNOS region. (Hepatology 2017;65:777-788).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.